










































Myeloid Cell and Transcriptome Signatures Associated With
Inflammation Resolution in a Model of Self-Limiting Acute Brain
Inflammation
Citation for published version:
Davies, CL, Patir, A & McColl, BW 2019, 'Myeloid Cell and Transcriptome Signatures Associated With
Inflammation Resolution in a Model of Self-Limiting Acute Brain Inflammation' Frontiers in Immunology, vol.
10, pp. 1048. DOI: 10.3389/fimmu.2019.01048
Digital Object Identifier (DOI):
10.3389/fimmu.2019.01048
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright © 2019 Davies, Patir andMcColl. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 08. Jul. 2019
ORIGINAL RESEARCH
published: 17 May 2019
doi: 10.3389/fimmu.2019.01048
Frontiers in Immunology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 1048
Edited by:
Robert Weissert,
University of Regensburg, Germany
Reviewed by:
Philip Alexander Efron,
University of Florida, United States
Sergei Kusmartsev,





This article was submitted to
Multiple Sclerosis and
Neuroimmunology,
a section of the journal
Frontiers in Immunology
Received: 27 November 2018
Accepted: 24 April 2019
Published: 17 May 2019
Citation:
Davies CL, Patir A and McColl BW
(2019) Myeloid Cell and Transcriptome
Signatures Associated With
Inflammation Resolution in a Model of
Self-Limiting Acute Brain Inflammation.
Front. Immunol. 10:1048.
doi: 10.3389/fimmu.2019.01048
Myeloid Cell and Transcriptome
Signatures Associated With
Inflammation Resolution in a Model
of Self-Limiting Acute Brain
Inflammation
Claire L. Davies 1, Anirudh Patir 2 and Barry W. McColl 3*
1Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh,
United Kingdom, 2 The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, United Kingdom, 3Centre for
Discovery Brain Sciences, UK Dementia Research Institute at The University of Edinburgh, The Chancellor’s Building,
Edinburgh BioQuarter, Edinburgh, United Kingdom
Inflammation contributes to tissue repair and restoration of function after infection or
injury. However, some forms of inflammation can cause tissue damage and disease,
particularly if inappropriately activated, excessive, or not resolved adequately. The
mechanisms that prevent excessive or chronic inflammation are therefore important to
understand. This is particularly important in the central nervous system where some
effects of inflammation can have particularly harmful consequences, including irreversible
damage. An increasing number of neurological disorders, both acute and chronic, and
their complications are associated with aberrant neuroinflammatory activity. Here we
describe amodel of self-limiting acute brain inflammation optimized to studymechanisms
underlying inflammation resolution. Inflammation was induced by intracerebral injection of
lipopolysaccharide (LPS) and the temporal profile of key cellular and molecular changes
were defined during the progression of the inflammatory response. The kinetics of
accumulation and loss of neutrophils in the brain enabled well-demarcated phases
of inflammation to be operatively defined, including induction and resolution phases.
Microglial reactivity and accumulation of monocyte-derived macrophages were maximal
at the onset of and during the resolution phase. We profiled the transcriptome-wide
gene expression changes at representative induction and resolution timepoints and used
gene coexpression network analysis to identify gene clusters. This revealed a distinct
cluster of genes associated with inflammation resolution that were induced selectively or
maximally during this phase and indicated an active programming of gene expression
that may drive resolution as has been described in other tissues. Induction of gene
networks involved in lysosomal function, lipid metabolism, and a comparative switch to
MHC-II antigen presentation (relative to MHC-I during induction) were prominent during
the resolution phase. The restoration and/or further induction of microglial homeostatic
signature genes was notable during the resolution phase. We propose the current model
as a tractable reductionist system to complement more complex models for further
understanding how inflammation resolution in the brain is regulated and as a platform
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for in vivo testing/screening of candidate resolution-modifying interventions. Our data
highlight how resolution involves active cellular and transcriptome reprogramming and
identify candidate gene networks associated with resolution-phase adaptations that
warrant further study.
Keywords: brain, inflammation, macrophage, microglia, neuroinflammation, neutrophil, resolution, transcriptome
INTRODUCTION
Acute inflammation is critical to stimulate tissue repair yet
if uncontrolled or insufficiently resolved can progress
to chronic inflammation that has potentially harmful
consequences (1). In the central nervous system (CNS), chronic
neuroinflammation and dysfunction of cells involved (e.g.,
microglia, recruited immune cells) is increasingly implicated in
the progression of neurodegenerative disease (2–6). Infection
as well as sterile damage to the CNS such as caused by stroke
and trauma, also elicit potent inflammatory responses (7, 8).
Chronic inflammatory responses to these acute events have
been proposed as a potential cause of long-term degenerative
and cognitive complications (9–11). There is therefore a need
to better understand mechanisms and to develop strategies that
prevent progression to harmful chronic neuroinflammation.
Understanding how self-limiting acute inflammatory reactions
in the CNS are regulated may help achieve this.
Acute CNS inflammation is underpinned by proliferation and
activation of brain-resident microglia (12) and, in some cases,
influx of blood-borne immune cells, notably neutrophils (13, 14),
and monocyte-derived macrophages (15–17). Collectively,
these myeloid cells are key orchestrators of the innate
immune response to CNS damage. Beneficial functions of
inflammatory cells include phagocytosis of debris (18–20),
provision of CNS barrier support (21, 22), and trophic support
for tissue healing and repair (22–25). Importantly, depletion
of certain innate immune cells can exacerbate CNS injury
and prevent timely repair (22, 26–28). However, in some
circumstances inflammation can be toxic and maladaptive.
Following cerebral ischemia, failure to resolve the initial
inflammatory response by removal of neutrophil toxins and
apoptotic cells can exacerbate injury (29). The impact of
controlling the severity of inflammation has been investigated
through immunomodulatory interventions. For example,
blocking interleukin-1, a critical mediator driving innate
neuroinflammation (30), improved outcome in experimental
stroke models (31) and has shown promise in clinical trials
(32, 33). Minocycline was promising in clinical trials following
ischaemic stroke (34–36). Nonetheless, other anti-inflammatory
treatments have been less successful in stroke (37, 38). In
traumatic brain injury, treatment with methylprednisolone
had a less favorable recovery (39) whilst progesterone had
no effect (40). These variable outcomes highlight that broad
suppression of inflammatory responses may also negate
possible beneficial effects of inflammation required for tissue
repair, and that a greater understanding of the endogenous
mechanisms that drive favorable resolution in the CNS
is warranted.
Inflammation resolution in tissues outside the CNS has
been more extensively studied, often using reductionist
models such as LPS or zymosan-induced peritonitis (41).
The utility of such models is underscored by their revealing
insight to fundamental principles including that resolution
is a highly active process and their identification of new
mediators, notably the specialized pro-resolving mediators
(SPMs) such as lipoxins, resolvins, and protectins (41–44).
Previous work highlighted that inflammatory mechanisms in
the brain may differ from peripheral tissues (30) therefore
it is unclear whether similar mechanisms and mediators
operate during resolution of CNS inflammation. A tractable
model of CNS inflammation optimized for probing cellular
and molecular components of the resolution phase is likely
to be a useful complement to more complex injury- and
disease-specific models.
Here, we present a self-limiting model of acute CNS
inflammation induced by intracerebral liposaccharide
injection that has a well-demarcated resolution phase. We
have determined the cellular profile and kinetics of key
myeloid cell accumulation as the inflammatory reaction
progresses from induction to resolution. We have also
generated a transcriptomic profile defining resolution that
highlights the active nature of the resolution phase and
identifies candidate pathways and mediators for future study.
The current work provides an experimental platform and
underpinning data to support further studies addressing




Male 8–12 week old C57bl/6J mice were purchased from
Charles River Laboratories and acclimatized for a minimum
of 1 week prior to procedures. Young adult male mice were
used to provide the broadest relevance for reference to existing
literature and comparisons with related models, the majority
of which have been conducted using male mice. A breeding
colony of Ccr2RFP mice [B6.129(Cg)-Ccr2tm2.1Ifc/J; Jax stock
#017586] as described previously (45) was maintained locally.
Mice were maintained under specific pathogen-free conditions
and a standard 12 h light/dark cycle with unrestricted access
to food and water. Mice were housed in individually ventilated
cages in groups of up to five mice. All procedures involving
live animals were carried out under the authority of a UK
Home Office Project License in accordance with the “Animals
(Scientific Procedures) Act 1986” and Directive 2010/63/EU and
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were approved by the local Animal Welfare and Ethics Review
Board (AWERB).
Intracerebral Injections
Mice were positioned in a stereotaxic frame (Stoelting, USA)
under isoflurane anesthesia (0.2 L/min O2 and 0.5 L/min
N2O). The skull was exposed via a midline incision and a
small craniotomy was made overlying the left hemisphere
2mm lateral to Bregma using an Ideal micro drill (tip
diameter 0.8mm) (Stoelting). Stereotaxic injections were
performed using pre-calibrated glass microcapillary pipettes
(Drummond Scientific, USA), previously pulled using a
vertical electrode puller (Model PP830, Japan). Co-ordinates
for intrastriatal injection were 2mm lateral to Bregma
(left hemisphere) and 2.5mm below the brain surface
(Franklin and Paxinos, 2007). One microliter LPS (E. coli
0127:B8, 5 mg/ml) or PBS was injected at a rate of 0.5
µL/min. The wound was sutured and topical local anesthetic
(lidocaine/prilocaine, EMLA) applied. Mice were recovered
from general anesthesia and returned to standard housing for
indicated durations. Post-operative dehydration was prevented
with subcutaneous saline injections. Mice were monitored
regularly during the post-operative period using a clinical
scoring system.
Tissue Processing
At indicated time points, mice were deeply anesthetized
with isoflurane (0.2 L/min O2 and 0.5 L/min N2O) and
perfused transcardially with physiological saline (0.1% DEPC-
treated for experiments proceeding to RNA extraction) to
remove circulating blood. For flow cytometry, the hemisphere
ipsilateral to injection was dissected and a brain cell suspension
prepared immediately as below. For transcriptomic profiling,
a 4mm brain sample block surrounding the injection site
was dissected from the ipsilateral hemisphere using a mouse
brain matrix and snap-frozen. For immunohistochemistry and
histology, after saline perfusion mice were perfused with 4%
paraformaldehyde. Brains were removed and post-fixed in 4%
paraformaldehyde for 24–48 h, cryoprotected in 20% sucrose
solution overnight then frozen by immersion in chilled (−40◦C)
isopentane. Twenty micrometer coronal sections were cut on
a freezing sledge microtome (Bright Instruments, Huntingdon,
UK) and stored in cryoprotectantmedium (100ml 10x phosphate
buffer, 300ml ethylene glycol, 200ml glycerol, 400ml dH2O)
at−20◦C.
Immunohistochemistry
Cryoprotected brain sections were placed into a 24-well plate
and washed in PBS. Endogenous peroxidase was blocked by
incubation with 0.3% hydrogen peroxide in dH2O for 15min
and sections washed in PBS. Sections were incubated in
5% normal serum (from species secondary antibody raised
in) diluted in 0.3% Triton/PBS for 1 h then in primary
antibody solution (2.5% normal serum in 0.3% Triton/PBS)
overnight at 4◦C. Primary antibodies used were: rabbit polyclonal
anti-IBA1 (Wako Chemicals, Japan), rabbit polyclonal anti-
neutrophils (batch SJC4, gift from D Anthony, University of
Oxford, UK), goat polyclonal anti-ICAM-1 (R&D Systems,
UK). Primary antibody staining was omitted for detection of
endogenous mouse IgG. Sections were then washed in PBS
and incubated with biotinylated secondary antibody (1:200 in
PBS; Vector Laboratories, UK) for 1 h. After further washes
in PBS, sections were incubated with avidin-biotin peroxidase
complex solution (Vectastain ABC, Vector, UK) for 1 h,
washed in PBS then incubated in diaminobenzidine (DAB)
solution (100 µl DAB, 2.5 µl H2O2 in 5ml dH20) for 30 s.
DAB solution was aspirated and sections rinsed with dH2O.
Sections were washed in PBS, mounted on gelatine-coated
slides and dried overnight then dehydrated in a series of
alcohols followed by incubation in xylene for 10min. Coverslips
were applied using Pertex medium (Cell Path Ltd., Newtown
Powys, UK).
To quantify neutrophil accumulation on SJC4-
immunostained sections, images were captured using a
Nikon N1 upright microscope (Nikon, Surrey, UK). Regions-
of-interest (ROI) were defined according to neuroanatomical
reference points around the site of injection (Figure 1A).
SJC4+ cells were marked on the digital images In Image
J using the cell counter to ensure they were only counted
once. The number of SJC4+ cells was counted in each of
the ROIs and data expressed as the sum of the numbers in
all ROIs.
Histology
Cryoprotected brain sections were washed in PBS, mounted
on to gelatine-coated slides and dried overnight at room
temperature. Sections were submerged in xylene, followed
by decreasing concentrations of alcohol. Sections were
rinsed in tap water and then incubated in haematoxylin
for 5min. Sections were washed in running tap water,
dipped in acid alcohol (0.5% HCl in 70% ethanol) and
then incubated in eosin for 5min. Sections were washed
in running tap water and then dehydrated in increasing
concentrations of alcohol. Finally, sections were incubated in
xylene for 5min and coverslips applied using Pertex mounting
medium (Cell Path Ltd, UK). Images of stained sections
were captured using a Nikon N1 upright microscope (Nikon,
Surrey, UK).
Flow Cytometry
Dissected brain samples were finely minced by scalpel blade in
ice-cold Hanks Balanced Salt Solution HBSS (Sigma-Aldrich),
centrifuged (400 g, 5min, 4◦C) resuspended and incubated for
1 h at 37◦C in digestion cocktail (50 U/ml collagenase, 8.5
U/ml dispase, 100 ug/ml Nα-Tosyl-L-lysine chloromethyl ketone
hydrochloride, 5 U/ml DNaseI in HBSS). Tissue was dissociated
using a Dounce homogeniser and the enzymatic reaction
terminated by addition of equal volume HBSS containing
10% fetal bovine serum. Homogenates were centrifuged (400 g,
5min, 4◦C) and pellets resuspended in 35% Percoll (GE
Healthcare, Sweden), overlaid withHBSS then centrifuged (800 g,
45min, 4◦C). The cell pellet was resuspended in FACS buffer
(DPBS containing 0.1% low endotoxin BSA). Cell suspensions
were added to a 96-well plate and low affinity Fc receptors
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FIGURE 1 | Kinetics of neutrophil accumulation and loss define operational phases of the inflammatory response to intracerebral LPS challenge. (A) Schematic
showing location of stereotaxic injections. Regions 1 and 2 indicate areas of cerebral cortex and striatum, respectively, shown in (B,D). (B) Representative
immunostaining images of SJC4+ neutrophil accumulation in cortex (top) and striatum (bottom) (regions indicated in A) 24 h after LPS injection. Scale bar, 100µm.
(Continued)
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FIGURE 1 | (C) Quantification of the total number of SJC4+ neutrophils in the ipsilateral hemisphere 24 h after PBS or LPS injection. ***P < 0.001, one-way ANOVA
with Dunnett’s post-hoc test. N = 4–5 mice/group. (D) Representative immunostaining images of SJC4+ neutrophils in the cortex (top) and striatum (bottom) (regions
indicated in A) following PBS or LPS injection and mice recovered up to 7 d. (E) Quantification of the total number of SJC4+ neutrophils following PBS or LPS
injection and recovered up to 7 d. **P < 0.01, one-way ANOVA with Bonferroni’s post-hoc test. N = 6 mice/group. (F) Flow cytometric identification of CD11b+
Ly6G+ neutrophils in brain cell suspensions. (G) Quantification of total number of CD11b+ Ly6G+ neutrophils following PBS or LPS injection and mice recovered for
up to 28 d. *P < 0.05, one-way ANOVA with Bonferroni’s post-hoc test. N = 4–7 mice/group. (H) Kinetics of neutrophil accumulation and loss following LPS injection
shown in (G) overlaid with the timings for the phases defined operatively in the current study as inflammation initiation/amplification (1–3 d) and resolution (3–5 d).
blocked by incubation of cells with anti-CD16/32 antibody for
30min. Plates were centrifuged (400 g, 5min), supernatants
discarded and cell pellets disrupted by gentle agitation of
plates. Cells were incubated with the following fluorochrome-
conjugated rat monoclonal antibodies for 30 min: anti-mouse
F4/80 (clone BM8, 1µg/ml, BioLegend); anti-mouse/human
CD11b (clone M1/70, 1µg/ml, BioLegend); anti-mouse CD45
(clone 30-F11, 1µg/ml, BioLegend), anti-mouse Ly6G (clone
1A8, 1µg/ml, BioLegend), and anti-mouse CD3 (clone 17A2,
1µg/ml, BioLegend). Plates were centrifuged (400 g, 5min),
supernatants discarded and cells resuspended in FACS buffer.
Anticoagulated (sodium citrate) blood samples were collected
from the tail vein. Fifty microliter blood was incubated
for 15min with anti-CD16/32 to block Fc receptors and
then for 15min with 1 µl each of fluorochrome-conjugated
rat monoclonal antibodies used at stock concentration: anti-
mouse/human CD11b (clone M1/70, BioLegend); anti-mouse
Ly6G (clone 1A8, BioLegend), anti-mouse Ly6C (clone HK1.4,
BioLegend) anti-mouse CD3 (clone 17A2, BioLegend), and anti-
mouse/human CD45R/B220 (clone RA3-6B2, BioLegend). Red
blood cells were lysed by addition of 450 µl FACS Lysing
solution (BD Biosciences) immediately before data acquisition.
Data for all samples were acquired using a LSR Fortessa (BD
Biosciences) and analyzed using Summit (Dako) or FlowJo
software. Compensation was performed using single-labeled
samples as references and positive regions of staining were
defined based on unstained samples. Gating and criteria for
identifying discrete cell subpopulations were as described in
the Results sections. For brain samples, the absolute number
of cells of a specific subset was determined from the number
of cells in the population divided by total viable cells,
multiplied by the total viable cell yield from the hemisphere
(derived from cell density calculated by haemocytometer on
the single cell suspension). For blood samples, cell densities
of specific subsets were computed from the number of cells
in the gated population divided by total viable cells multiplied
by the total blood leukocyte count (/ml) Mean fluorescent
intensities (MFI) of selected cell populations were derived
directly from software.
RNA Extraction for Microarray
RNA was extracted from a 4mm brain sample centered
on the injection site dissected using a mouse brain matrix
from the hemisphere ipsilateral to injection at indicated
timepoints using the miRNeasy Mini kit (Qiagen) according to
manufacturer’s instructions. RNA quantities were determined
by Nanodrop 1000 (Thermo Fisher Scientific, MA, USA)
and RNA quality assessed using the Agilent Bioanalyzer
(Agilent Technologies, CA, USA) and all samples passed
a quality control threshold (RIN ≥7) to proceed to gene
expression profiling. For microarrays, each biological replicate
(n = 3) contained tissue pooled from three mice in a
randomized manner and containing equivalent quantities of
RNA from each constituent sample. Based on our previous
experience using microarrays, this approach provides sufficient
biological replication to maintain statistical power through
minimizing inter-replicate variance. Constituent (unpooled)
samples (n = 9) were also retained for validation by
qPCR (see below).
RNA Extraction for qPCR
Unpooled samples were used for qPCR assays. Isolated mixed
cell suspensions prepared as above for flow cytometry were
stored in RNAlater at −80◦C. RNAlater was removed and cells
were resuspended in 0.75ml TRIzol, mixed to lyse cells, and
incubated at room temperature for 5min. 0.2ml 1-Bromo-3-
chloropropane was added to samples and shaken vigorously for
15 s, then incubated for 3min at room temperature. Samples were
centrifuged at 12,000 × g for 15min at 4◦C, and upper aqueous
phase was collected. Another 0.2ml 1-Bromo-3-chloropropane
was added and repeated. One microliter of neat linear acrylamide
and 0.5ml 100% isopropanol were added to the aqueous phase
and incubated at room temperature for 10min. Samples were
centrifuged at 12,000 × g for 10min at 4◦C. Supernatant was
removed and the pellet was washed in 1ml 75% ethanol. Samples
were centrifuged at 7,500× g for 5min at 4◦C, and pellet was then
air-dried at room temperature. The pellet was resuspended in 30
µl RNase free water, incubated at 60◦C for 10min and quantity
determined by Nanodrop 1000.
Transcriptomic Profiling and
Computational Analysis
Microarray assays were performed by Edinburgh Genomics,
University of Edinburgh (https://genomics.ed.ac.uk/) as
described previously (46). Total RNA was labeled using
the IVT Express Kit (Affymetrix). First-strand cDNA was
synthesized and converted to double-stranded DNA template
for transcription and synthesis of aRNA incorporating a biotin-
conjugated nucleotide. aRNA was purified and fragmented
prior to hybridization on Affymetrix arrays. Biotin-labeled
aRNA was hybridized to the whole mouse genome HT MG-430
PM array plate (Affymetrix, CA, USA) representing >39,000
transcripts, using the GeneTitan multi-channel instrument
(Affymetrix). Microarray datasets were normalized by the
Robust Multiarray Averaging (RMA) method in Affymetrix
Expression Console (Affymetrix, CA, USA) and analysis
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performed using the ht_mg-430_pm.na36 annotation release
(Affymetrix). Genes differentially expressed among treatment
groups were determined by ANOVA with FDR correction
using Affymetrix Transcriptome Analysis Console (TAC)
and differentially expressed genes visualized by heat map.
Transcripts significantly altered in expression (FDR q < 0.05,
fold change ≥1.5) in LPS compared to PBS-treated mice were
determined in TAC and log-transformed data visualized by
volcano plot. For gene coexpression network analysis, a pairwise
transcript-to-transcript coexpression matrix was computed
in Graphia Pro (https://kajeka.com/graphia-professional/;
Kajeka, UK) from the set of differentially-expressed transcripts
among all treatments (determine in TAC as above) using a
Pearson correlation threshold r ≥ 0.95. A network graph
was generated where nodes represent individual probesets
(transcripts/genes), and edges between them the correlation
in expression pattern across treatment groups. The graph was
clustered into discrete groups of transcripts sharing similar
expression profiles using the Markov clustering algorithm
in Graphia (inflation = 2.2). Transcript content of key
clusters was inspected manually. Cluster enrichment for Gene
Ontology (GO) biological processes and cell components was
determined in DAVID (https://david.ncifcrf.gov/) using default
criteria. Microarray datasets are available at NCBI GEO with
accession GSE122815.
Quantitative PCR
cDNA was synthesized from DNase-treated RNA samples using
Superscript III Reverse Transcriptase (Life Technologies)
according to manufacturer’s instructions. Primers were
designed using Primer BLAST (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/) and validated to ensure adequate





Gapdh was used as the housekeeping gene. cDNA was
mixed with forward and reverse primers, ROX reference
dye and Platinum SYBR Green qPCR Supermix-UDG in
DNase/RNase-free water and qPCR cycles performed on
a Stratagene Mx3005P thermocycler (Agilent) as follows:
hot-start denaturation cycle 95◦C for 10min, 40 cycles of
amplification at 95◦C for 15 s, 60◦C for 20 s, and 72◦C for
1min, followed by one cycle of 95◦C for 1min, 55◦C for
30 s, and 95◦C for 30 s. Cycle threshold (Ct) values of target
genes were normalized to Gapdh and data are expressed
as fold change relative to control group (PBS) using the
2∧(−11Ct) method.
Experimental Design and Statistical
Analysis
Estimates of sample size were determined from previous data
(30) to achieve a power of 0.8 at P < 0.05. Data were
analyzed using GraphPad Prism v6 (GraphPad Software Inc.,
CA, USA). One-way ANOVA with post-hoc correction was
used for comparisons across multiple groups (Bonferroni) or to
compare selected groups to control (Dunnett). For quantitative
PCR, data were analyzed using a one sample t-test compared
to PBS (reference value of 1 for the PBS group). Design and
analysis of transcriptome data are described above. Analysis
was performed unware of allocation to experimental group
however no formal blinding procedure was used. Data are
presented as mean ± SEM unless otherwise stated. ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. P ≤ 0.05 was
considered statistically significant. False discovery rate (FDR)
correction was applied for analysis of raw transcriptomic data as
described above.
RESULTS
Acute Intracerebral LPS Challenge Induces
a Self-Limiting Inflammatory Response
With Demarcated Induction and Resolution
Phases
Neutrophils are defining cells of innate immune reactions and
in tissues outside the CNS, the kinetics of their accumulation
and loss in response to inflammatory stimuli, such as LPS,
has been useful to operatively define different phases of the
inflammatory response (41). We first assessed the effects of
escalating doses of intrastriatal LPS injection on neutrophil
accumulation 24 h after injection by immunohistochemistry
(Figures 1A–C). As expected, in vehicle-injected mice there
were negligible neutrophils evident in brain tissue. All doses
of LPS induced marked accumulation of neutrophils in the
brain parenchyma as well as increased numbers of neutrophils
localized to the luminal and abluminal surfaces of blood
vessels. Neutrophils were distributed throughout the striatum
and the overlying motor and somatosensory cerebral cortex
(Figure 1B). There was a concentration-dependent increase in
the total number of neutrophils accumulating in brain tissue
(incorporating parenchymal and vascular-associated cells) 24 h
after LPS injection (Figure 1C). For further studies, we selected
the highest concentration of LPS (5 µg/µl) given the robust
and consistent response. We next assessed the temporal profile
of neutrophil recruitment after LPS injection. As above, LPS
inducedmarked neutrophil accumulation 24 h after injection and
similar numbers were evident at 72 h (Figures 1D,E). In contrast,
by 5 d after injection there were few neutrophils remaining and
a negligible number of cells was also evident at 7 d suggesting
the infiltration had almost completely resolved by this time-
point. To corroborate and extend this profile we used flow
cytometric quantification of brain cell suspensions. Neutrophils
were clearly identified as a distinct population of CD11b+Ly6G+
cells (Figure 1F). Consistent with immunostaining data, there
were few neutrophils in vehicle-injected mice and a marked
increase in numbers was detectable at 24 h after injection that
peaked at 72 h (Figure 1G). Thereafter, neutrophil numbers
declined markedly by 5 d and further toward control levels
by 7 d where they remained stable until 28 d after injection.
Using the above data we could operatively define different
phases of the evolving inflammatory reaction, including a
well demarcated resolution phase (Figure 1H). We defined
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the induction/amplification phase as the initial 24 h period
after injection, the plateau phase from 24 to 72 h reflecting
the largely stable levels of neutrophils, and the resolution
phase from 72 h onwards which is reflective of the decline in
neutrophils from peak levels toward baseline. Thus, intrastriatal
injection of LPS induces an acute self-limiting inflammatory
reaction with well-demarcated induction and resolution phases
as defined according to intracerebral neutrophil accumulation
and loss.
Temporal Changes to the
Cerebrovasculature and
Microglia/Macrophages in Relation to
Induction and Resolution Phases
Changes to the adhesive properties and permeability of the
vascular endothelium as well as reactivity in tissue macrophages
are archetypal features of inflammatory responses.We performed
an initial qualitative assessment of selected markers to
understand how gross changes to the cerebrovasculature
and microglial/macrophage population evolved in relation to
the phases of inflammation defined above. Immunoreactivity
of ICAM-1 (Figure 2A), an adhesion molecule induced in
inflamed endothelium that mediates leukocyte transmigration,
was undetectable in vehicle-injected brain but was induced
24 h after LPS injection. Further induction, reflected by greater
intensity of immunostaining, occurred at 5 d and thereafter there
was declining expression. Permeability of the blood-brain barrier
(BBB), a key property of the brain microvascular endothelium,
was assessed by leakage of endogenous IgG, which is normally
prevented from entering the brain by the BBB. Alterations
in IgG immunostaining were largely confined to the injected
hemisphere (Figure 2B). A focal area of IgG immunoreactivity
within the striatum was evident 24 h after LPS injection and
this extended to the entire striatum and most cortical areas
at the coronal plane of injection 3–7 d after injection. IBA1
immunostaining was used to assess the general pattern of
microglia/macrophage reactivity and in vehicle-injected brains
immunoreactivity was characteristic of ramified microglia
evenly distributed throughout the parenchyma (Figure 2C).
The intensity of IBA1+ cells within the ipsilateral striatum
and cortex increased 24 h after LPS injection and there was
evidence of hypertrophy of cell bodies indicative of microglial
activation. At later time-points (3–7 d), there were modest
increases in the density of IBA1+ cells (see flow cytometry
data below for quantification) and a markedly greater range
of cell morphologies and intensities evident. This included
ramified cells with an intense, hypertrophic cell soma similar
to those observed at 1 d and the appearance of cells with
thickened, short processes and much larger, very intensely-
stained cells largely devoid of processes (Figure 2C). This
pattern indicated an increasing heterogeneity of the IBA1+
population from 3 d onwards coinciding with the resolution
phase and likely reflected reactive changes in resident microglia
and the accumulation of monocyte-derived macrophages. We
also noted that there was negligible if any signs of microglial
reactivity in vehicle-injected mice suggesting the mechanical
nature of the injections themselves was not an inflammatory
trigger and consistent with the absence of histological signs of
trauma (Figure 2D).
Accumulation of Monocyte-Derived
Macrophages Coincides With the Onset of
Inflammation Resolution
In view of the immunohistochemistry observations suggestive
of an evolving mixed microglial/macrophage population in
LPS-injected brains, we used flow cytometry to investigate the
myeloid cell composition more thoroughly and quantitatively.
Combinatorial expression of a panel of myeloid cell markers
(CD11b, Ly6G, CD45) enabled identification of distinct
phenotypic subpopulations. In vehicle-injected brains a
relatively homogenous population of CD11b+CD45loLy6G−
cells was evident whereas after LPS injection additional CD11b+
populations appeared (Figure 3A). These included a Ly6G+
population (operationally defined as neutrophils for the present
study) and two major subsets of CD11b+Ly6G− cells that could
be distinguished on the basis of differential CD45 expression
intensity. We operationally defined CD11b+Ly6G−CD45lo cells
as microglia (i.e., resident macrophages of the brain parenchyma)
and CD11b+Ly6G−CD45hi cells as recruited monocytes
(Mo)/monocyte-derived macrophages (Mo/MDMs) (a small
proportion may comprise perivascular and/or choroid plexus
macrophages also present in veh-injected mice) (Figure 3A).
It should also be noted that the Ly6G+ and Ly6G− CD45hi
recruited populations may comprise cells at various stages of
differentiation that may include myeloid-derived suppressor
cells (MDSCs) (47). Although microglial CD45 expression
can be induced in the inflamed state, previous studies have
shown that differential CD45 intensity reliably distinguishes
these different sources. Indeed, in the present study at all
time-points after LPS injection, mean CD45 intensity on
the CD11b+Ly6G−CD45hi population was 5–10-fold greater
including when microglial CD45 intensity was induced to
its maximum (almost doubling) at 3 d (Figures 3B, 4B).
The number of total CD11b+ cells increased in LPS-injected
brains reaching a peak 3 d after injection and declining to
near baseline levels by 28 d (Figure 3C). The number of
CD11b+Ly6G−CD45lo microglia did not significantly increase
in response to LPS challenge (Figure 3D). Negligible numbers
of CD11b+Ly6G−CD45hi cells were present in vehicle-injected
brains and a marked increase in number was evident after
LPS challenge with maximal accumulation 3 d after injection
and a gradual decline thereafter (Figure 3E). To corroborate
these findings and ensure there was no misidentification of
microglia and Mo/MDMs using differential CD45 expression,
we performed a separate experiment using heterozygous
Ccr2RFP/+ reporter mice that express RFP in monocyte-derived
cells but not microglia. RFP+ cells were largely absent from
vehicle-injected brains whereas a clear accumulation of RFP+
cells was observed 3 d after LPS injection (Figure 3F). RFP
expression was only found in Ly6G− cells that were also
expressing high levels of CD45 and not in CD11b+CD45lo
cells and almost all CD11b+CD45hi cells were positive for
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FIGURE 2 | Temporal profile of cerebrovascular and gross CNS macrophage changes after intracerebral LPS challenge. Representative images of (A) cortical ICAM-1
and (B) IgG immunostaining at indicated timepoints after intracerebral LPS challenge indicate changes in cerebrovascular activation and blood-brain permeability. (C)
Representative images of cortical IBA1 immunostaining at indicated timepoints after intracerebral LPS challenge. Morphological changes in IBA1+ cells from ramified
in PBS-treated mice to intensely IBA1+ with shorter processes (1 d, arrowheads) and hypertrophic (5 d, black and red arrows) after LPS challenge were evident.
(D) Representative images of haematoxylin and eosin (H & E) staining indicated no overt neuronal pathology caused by LPS injection. Scale bar: 100µm (A,D);
50µm (C).
RFP expression (Figure 3G). These data confirm the influx of
Mo/MDMs and validate the use of differential CD45 expression
to distinguish resident and recruited CNS macrophages in
this model. This also excludes the theoretical possibility
that the increase in number of CD11b+Ly6G−CD45hi cells
in response to LPS is predominantly an expansion of the
perivascular macrophage population (which express higher
levels of CD45 compared to parenchymal microglia) because
previous studies have shown these are not derived from and
do not turnover from CCR2-dependent (RFP+) bone marrow
precursors (48). Alongside accumulation of blood-derived
immune cells in the brain, we also observed elevated numbers
of neutrophils and monocytes in the blood in response to
intracerebral LPS challenge (Supplementary Figure 1), similar
to our previous study (30), and indicative of a systemic myeloid
cell mobilization likely contributing to the trafficking of cells
into the inflamed brain. Overall, the flow cytometry data
are consistent with the immunohistochemistry observations
of a heterogeneous microglial/macrophage population and
show that a marked accumulation of recruited blood-derived
Mo/MDMs coincides with the onset of resolution 3 d after
LPS injection.
The Peak of Microglial Reactivity
Corresponds With the Inflammation
Resolution Phase
As described above, morphological signs of microglial reactivity
were evident during both the induction and resolution phases,
although appeared most prominent during resolution. Using
flow cytometry, we analyzed expression intensities of general
markers of microglial/macrophage reactivity and maturation,
CD45 and F4/80, specifically on the microglial population
(CD11b+Ly6G−CD45lo cells as above). Mean fluorescence
intensity of both microglial CD45 and F4/80 increased
significantly in response to LPS injection (Figures 4A–D).
This induction was relatively modest at 24 h after injection
(induction phase) but was maximal at 3–5 d thus coinciding
with the resolution phase and suggesting the magnitude of gross
microglial reactivity peaks during resolution (Figures 4A–C).
Comparison of peak CD45 (3 d) (Figures 3B, 4B) and F4/80 (5
d) (Figures 4C,D) expression levels in microglia with those in
Mo/MDMs at the corresponding time-point after LPS challenge
confirmed that, despite 2-fold induction of CD45 and 5-
fold induction of F4/80 compared to vehicle-injected mice
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FIGURE 3 | Temporal profile of microglial and monocyte-derived macrophage recruitment after intracerebral LPS challenge. Brain cell suspensions were prepared
from the ipsilateral hemisphere after intrastriatal PBS or LPS injection at indicated timepoints. (A) Representative flow cytometry dot plots and regions defining
selected myeloid cell subsets (annotated at 1 d timepoint after LPS) based on Ly6G+ and CD45+ labeling (with pre-gating on CD11b+CD3− cells). Neutrophils were
defined as Ly6G+CD45hi, microglia as Ly6G−CD45lo, and monocyte-derived macrophages (Mo/MDM) as Ly6G−CD45hi. Dot plots show representative changes in
the composition of cell subsets as time progresses after LPS challenge. (B) Quantification of CD45 expression intensity in microglia 3 d after LPS with MDM
expression shown for reference. **P < 0.01, Student’s t-test. Quantification of the total number of (C) CD11b+ cells, (D) CD11b+CD3−Ly6G−CD45lo microglia, and
(E) CD11b+CD3−Ly6G−CD45hi Mo/MDMs in the ipsilateral hemisphere after PBS or LPS injection. *P < 0.05, one-way ANOVA with Bonferroni’s post-hoc test. (F)
Quantification of the total number of CD11b+Ly6G−RFP+ MDMs after 3 d after intrastriatal PBS or LPS injection in Ccr2RFP/+ reporter mice. (G) Representative flow
cytometry dot plot showing relationship between RFP and CD45 expression in brain cell suspensions from Ccr2RFP/+ reporter mice 3 d after intrastriatal LPS injection.
in microglia, expression remained markedly lower than in
Mo/MDMs (∼10-fold lower for CD45;∼2-fold lower for F4/80).
In agreement with the above flow cytometry data, mining of
microarray data (see below for details) showed that expression
levels of the genes encoding CD45 and F4/80, Ptprc and Emr1,
were significantly elevated in LPS-injected brain homogenates
and greatest during the resolution phase (Figure 4E) (NB: we
are not excluding that this will also partly reflect the greater
number of CD45hi cells that accumulate during this phase
as shown in Figure 3). Overall, these data suggest that the
resolution phase is associated with a particularly reactive state
of resident microglia that occurs alongside the recruitment
of Mo/MDMs.
Inflammation Resolution Is Associated
With de novo Induction of a Unique
Transcriptional Programme
The above data show some of the key cellular changes associated
with resolution of acute brain inflammation. We next sought
to determine if inflammation resolution was associated with
expression of distinct transcriptional networks by using a
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FIGURE 4 | Markers indicative of the magnitude of microglial reactivity peak at the onset of and during the resolution phase after intracerebral LPS challenge. (A)
Brain cell suspensions were prepared from the ipsilateral hemisphere after intrastriatal PBS or LPS injection at indicated timepoints. Representative histograms
showing expression of CD45 (top panel) and F4/80 (bottom panel) in CD11b+Ly6G−CD45lo microglia. Quantification of the mean fluorescence intensity of (B) CD45
and (C) F4/80 in CD11b+Ly6G−CD45lo microglia. **P < 0.01, Student’s t-test (B); **P < 0.01, Mann–Whitney test (C), respectively. (D) Change in mean fluorescence
intensity in CD11b+Ly6G−CD45lo microglia of F4/80 5 d after LPS compared to PBS shown with CD11b+Ly6G−CD45hi MDM CD45 intensity shown for reference.
**P < 0.01, Mann–Whitney test. (E) Gene expression intensity of Ptprc and Emr1 measured by microarray from brain homogenates isolated from the ipsilateral
hemisphere after intrastriatal PBS or LPS injection at indicated timepoints. *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA with Bonferroni’s post-hoc test.
transcriptome-wide approach to profile gene expression at
resolution and induction phases and in the uninflamed state
(PBS injection). On the basis of cellular data described above,
we selected 4 d after LPS (resolution) and 1 d after LPS
(induction) as representative of the different phases of the
inflammatory response. One thousand seven hundred and
seventy-nine transcripts were differentially expressed across
all treatment groups (ANOVA with FDR q < 0.05) and a
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heat-map of these transcripts demonstrated distinct patterns of
altered gene expression from the uninflamed state and between
resolution and induction phases (Figure 5A). Expression of a
negligible number of transcripts was suppressed 1 d or 4 d
after LPS compared to PBS injection therefore we focussed
on upregulated transcripts. Expression of 723 transcripts was
significantly increased (FDR q< 0.05, fold-change≥1.5) 1 d after
LPS and 534 transcripts 4 d after LPS compared to PBS injection
(Figure 5B). We identified 396 induction phase-specific and 207
resolution phase-specific transcripts, respectively, based on these
filtering criteria (Figure 5C). This provided an initial indication
that resolution was associated with induction of a unique de novo
transcriptional programme.
Co-expression Network Analysis and
Represented Functional Pathways of
Inflammation Induction and Resolution
To explore the composition of the transcriptional networks
underpinning resolution and their differences with the induction
phase in more depth we constructed a gene co-expression
network graph and non-subjectively clustered into groups of
highly co-expressed genes. Four major clusters of co-expressed
genes dominated the network graph (clusters 1–4) (Figure 6A)
and we therefore focussed further attention on these. The mean
expression profile of each of the major clusters showed a distinct
profile (Figure 6B): cluster 1 showed increased expression
relatively selectively 1 d after LPS challenge (hereafter referred to
as the induction-selective cluster); cluster 2 showed the opposite
pattern with increased expression relatively selectively 4 d after
LPS challenge (hereafter referred to as the resolution-selective
cluster); cluster 3 showed increased expression at both 1 d and
4 d after LPS challenge with relatively greater expression at 4 d
(hereafter referred to as the resolution-dominant cluster); cluster
4 also showed increased expression at both 1 d and 4 d after LPS
challenge but with relatively greater expression at 1 d (hereafter
referred to as the induction-dominant cluster). We manually
inspected the contents of each cluster and an overall summary
is presented in Supplementary Table 1—here we largely focus
on the induction- and resolution-selective clusters summarized
in Figure 6C.
The induction-selective cluster (cluster 1) contained 419
nodes/transcripts. Manual inspection of the cluster revealed
a number of functional classes of genes consistent with a
co-ordinated role in sensing, initiation and amplification of an
innate immune response (Figure 6C, Supplementary Table 1).
These included Toll-like receptors (Tlr3), scavenger receptors
(Marco, Msr1), cytokines (Il1, Il6), endothelial adhesion
molecules (Icam1, Vcam1, Madcam1), and chemokines of
both CC (Ccl2/3/4/7/12) and CXC classes (Cxcl1/2/10/11).
Further chemokines (Ccl5/6/9/19) were present in the induction-
dominant cluster (cluster 4). There was a particularly notable
presence of a large number of interferon-regulated genes
of the Ifi, Ifit, and Ifitm families in the induction-selective
cluster suggestive of potent interferon signaling during this
phase. This was further evident by the large number of
classical (H2-D1, H2-K1, H2-Q7) and non-classical MHC
class I (H2-Q6, H2-T10) genes collectively contained with
the induction-selective and –dominant clusters. In contrast,
MHC class II genes were not present within the induction
clusters. Consistent with this pattern of interferon and MHC
class I gene expression during the induction phase, several
transcription factors regulating these pathways were evident
in the induction-selective cluster including from the Irf family
(Irf1/7/9), the Stat family (Stat1/2/3) and the master regulator
of MHC class I expression, Nlrc5. Other transcription factors
contained within the induction-selective and -dominant clusters
included genes encoding several components of NF-κB (Rela,
Relb, Nfkb2) and from the Cebp family (Cebpb, Cebpd) that
are consistent with induction of a range of inflammatory
mediators described above. In support of the above observations,
GO enrichment analysis revealed over-representation of the
biological processes “chemotaxis,” “response to interferon-
alpha,” “response to interferon-beta,” and “antigen processing
and presentation of exogenous peptide antigen via MHC class I”
(Supplementary Table 2). Collectively, these data indicate a
potent innate immune transcriptional programme during the
induction phase featuring a prominent interferon andMHC class
I response among an array of broader inflammatory signaling.
The resolution-selective cluster (cluster 2) contained 347
nodes/transcripts and comprised groups of functionally-related
genes distinct from those in the induction clusters emphasizing
the engagement of transcriptional networks specific to the
resolving phase (Figure 6C, Supplementary Table 1). In contrast
to the induction clusters, which contained a prominent MHC
class I gene set (see above), genes encoding proteins involved
in antigen processing and presentation on MHC class II (H2-
Aa, H2-Ab1, H2-Eb1, Ifi30, Cd74) were selectively present in the
resolution-selective cluster suggestive of differing involvement
of the type of antigen processing and presentation as the
inflammatory response evolves. Of particular note, an array of
genes encoding lysosomal proteins was evident in the resolution-
selective cluster which included the lysosomal membrane
protein-encoding Lamp1, Laptm5, and Cd68 and a range of
protease-encoding genes such as the cathepsins (Ctsa/b/h/s/z),
glycosidases (Gusb), hexosaminidases (Hexa, Hexb), legumain
(Lgmn), lipases (Lipa) lysozymes (Lyz1, Lyz2), and sulfatases
(Gns). This set of genes is indicative of enhanced lysosomal
activity and phagocytosis and further highlights the induction
of MHC class II pathway given the important role for
endo-lysosomal cathepsins in peptide processing and loading
for antigen presentation (49). Further functional classes of
genes of interest in the resolution-selective cluster included
lipid metabolism (Apobec1, Apoc2, Apoe, Lipa, Npc2) and
the complement pathway (C1qa/b/c, C3ar1). In support of
the above findings, GO enrichment analysis revealed over-
representation of the biological processes “antigen processing
and presentation of exogenous peptide antigen via MHC
class II,” “lipoprotein biosynthetic process,” “cholesterol eﬄux,”
“proteolysis involved in cellular protein catabolic process,” and
“phagocytosis, engulfment” (Supplementary Table 3) among
general immune response enrichment as well as the cellular
component “lysosome” (Supplementary Table 4). It was also
evident that a distinct set of transcription factors, including
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FIGURE 5 | Transcriptome profiling identifies unique sets of genes induced at the induction and resolution phases of the inflammatory response after intracerebral
LPS challenge. Brain homogenates were prepared from the ipsilateral hemisphere after intrastriatal PBS or LPS injection at indicated timepoints and transcriptome
profiling by microarray performed. (A) Visualization by heat map of the 1779 transcripts differentially expressed across all treatment groups (ANOVA with FDR q <
0.05) and hierarchical clustering of samples according to the transcript expression patterns. Note the distinct modules of transcripts selectively altered 1 d (induction
phase) and 4 d (resolution phase) after LPS injection. (B) Visualization of the transcripts differentially expressed 1 d or 4 d after LPS compared to PBS injection (FDR q
< 0.05, fold-change ≥1.5) by volcano plot. (C) Venn diagram depicting the overlapping and unique transcripts significantly induced 1 d or 4 d after LPS compared to
PBS injection (FDR q < 0.05, fold-change ≥1.5).
Cebpa, Irf8, Mafb, and Spib were present in the resolution-
selective cluster which is consistent with regulation of myeloid
cell differentiation/maturation and the flow cytometry data
described above. Overall, these data reinforce the distinctive
nature of the regulatory and transcriptional networks controlling
the resolution phase and in particular suggest lysosomal
function as central to multiple co-ordinated pro-resolution
molecular processes.
Inflammation Resolution Involves
Induction or Restoration of Homeostatic
Microglial Gene Expression
Recent studies examining the transcriptional basis of microglial
identity have described a set of genes highly enriched inmicroglia
compared to systemic myeloid cells and other CNS cell types (46,
50–53). This expression signature has been proposed to reflect a
homeostatic microglial state (54).We noticed that the resolution-
selective cluster contained a considerable number of these
microglial signature genes, including Fcrls, Hexa, Hexb, Olfml3,
Rnase4, Tmem119, and Trem2 (Figure 6C). The expression of all
these genes was significantly increased 4 d after LPS challenge
compared to 1 d and also after PBS treatment (Figure 7A).
Expression of P2ry12 and P2ry13, further proposed homeostatic
microglial signature genes, was also elevated 4 d compared to 1
d after LPS challenge (Figure 7B) although this largely reflected
a restoration of suppressed expression levels and is consistent
with the known instability of these genes in response to LPS or
other overtly pro-inflammatory conditions. We did not observe
changes in microglial numbers during the transition from
induction to resolution phases (see Figure 3 above) therefore
gene expression changes are likely the result of actual quantitative
expression changes. Trem2 is a member of a receptor family that
in mice also contains Trem1 and Trem3. In contrast to Trem2,
expression of Trem1 and Trem3 was selectively induced 1 d
after LPS challenge (Figure 7C) in keeping with their presence
in the induction-selective cluster and known functionally distinct
role from Trem2 in amplification of innate immune signaling
(55). We validated the microarray expression pattern of the
Trem genes by qPCR on myeloid cell-enriched cell suspensions
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FIGURE 6 | Gene coexpression analysis of transcriptome data after intracerebral LPS challenge shows distinct clusters of coexpressed genes including a
resolution-specific cluster. Brain homogenates were prepared from the ipsilateral hemisphere after intrastriatal PBS or LPS injection at indicated timepoints and
transcriptome profiling by microarray performed. (A) Gene coexpression network graph of the 1,779 transcripts differentially expressed across all treatment groups.
The coexpression matrix was clustered using a Markov clustering algorithm and the major clusters of coexpressed transcripts are highlighted. (B) Mean expression
profiles of clusters 1–4 across all treatment groups derived from all transcripts in each cluster. (C) Clusters were manually inspected for transcript composition.
Selected gene families of interest over-represented in cluster 1 (induction-selective) and cluster 2 (resolution-selective). For full summary of clusters 1–4 see
Supplementary Table 1.
Frontiers in Immunology | www.frontiersin.org 13 May 2019 | Volume 10 | Article 1048
Davies et al. Inflammation Resolution in the Brain
FIGURE 7 | Changes in expression of microglial signature genes after intracerebral LPS challenge suggest restoration of a homeostatic microglial state is associated
with inflammation resolution. Brain homogenates were prepared from the ipsilateral hemisphere after intrastriatal PBS or LPS injection at indicated timepoints and
gene expression measured by (A–C) microarray or (D) quantitative PCR. Expression intensities of (A) selected microglial homeostatic signature genes, (B) P2Y
(Continued)
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FIGURE 7 | receptor genes, and (C) amplifying TREM family genes. *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA with Bonferroni’s post-hoc test. (D)
Relative expression of Trem1 and Trem2 after LPS vs. PBS injection at indicated timepoints. *P < 0.05, one sample t-test compared to PBS (reference value of 1 for
the PBS group).
isolated from the brain over an extended time-course after LPS
challenge. This showed the same opposing pattern of Trem1 and
Trem2 expression and with similar kinetic profile as microarray
analysis (Figure 7D). Overall, these data suggest that resolution
of acute brain inflammation is associated with induction and/or
restoration of “homeostatic” microglial signature genes and a
transition in the balance of amplifying and modulatory immune
signaling via immunoreceptors such as TREM1 and TREM2.
DISCUSSION
In the present study, we sought to develop and validate a model
tailored for studying the resolution of acute brain inflammation
and in doing so define its key cellular and molecular
characteristics. Several interesting observations emerged, notably
that the resolution phase appears to be a very active period of
transcriptomic reprogramming temporally aligned with marked
changes in myeloid cell composition and reactivity. The very
dynamic nature of this phase points to its potential for
manipulation and subversion thus understanding endogenous
regulatory mechanisms and factors perturbing them will be
important in future. The baseline data provided here provide
a platform for future studies to uncover novel CNS resolution
mechanisms and modifiers.
We used LPS as the inflammatory challenge which has
both strengths and weaknesses. As a cell wall component of
gram-negative bacteria, LPS is relevant to infectious challenges
of the brain. Although rare, infection of the central nervous
system parenchyma often has severe consequences (56) and
it is important to consider previous studies that indicated
an unrestrained host inflammatory response to infection may
be more problematic than direct pathogen-induced toxicity
(57). LPS is also likely relevant to broader contexts of sterile
inflammation given its actions are mediated by signaling through
TLR4. Other ligands for TLR4 include a number of damage-
associated molecular patterns (DAMPs), such as HMGB1 and
S100A8/9, which are produced and/or exposed by cell death and
other triggers of sterile inflammatory responses important in the
reaction to brain hypoxia/ischaemia, trauma (58, 59). Microbial
and sterile challenges can result in conserved TLR4 signaling
responses (e.g., MAP kinase, NF-κB, and HIF-1 activation)
that induce closely overlapping transcriptional and metabolic
reprogramming profiles. Indeed, our unpublished data suggest a
substantial degree of overlap in the transcriptome-wide changes
in gene expression in response to intracerebral LPS injection or
experimental stroke in mice. In the present study there was no
evidence that LPS injection caused neuronal toxicity therefore
the initial inflammatory response should reflect a direct response
to LPS thus exposure to a highly consistent stimulus is achieved.
In most models of acute brain injury, cell death is a key feature
but often is variable in magnitude and distribution. In some
cases, it will be necessary to include the complexity of processes
inherent in acute brain injuries (e.g., cell death, oedema, blood
flow alterations) but in other instances it may be advantageous to
use a more reductionist but nonetheless representative system as
described here.
Mechanisms of inflammation resolution have been studied
extensively in tissues outside the brain. The utility of reductionist
models is emphasized by their leading to the discovery of
novel pro-resolving mediators, notably several classes of fatty
acid-derived molecules (60). Models used have included the
intraperitoneal injection of LPS or zymosan and the air-pouch
inflammationmodel (41, 61, 62). Key features of these models are
the ability to analyse compartmentalized tissue/fluid extracts with
precise monitoring of kinetic profiles of molecular and cellular
changes. In common with these models, we observed a range of
cellular changes characteristic of an acute inflammatory response
regardless of tissue location, including resident macrophage
activation, increased vascular permeability and endothelial
activation, and myeloid cell recruitment consisting of early
neutrophil accumulation and a slower influx of monocyte-
derived cells. Detailed analysis in a murine acute peritonitis
model produced quantitative indices for the temporal evolution
of key cellular changes, including the resolution index based on
the relationship between neutrophil and monocyte accumulation
(41). In the present study, neutrophil accumulation peaked 1–3
d after LPS injection and there were negligible numbers by 5 d
indicating a relatively rapid removal of these cells from the brain.
We estimated the resolution index (time for neutrophil numbers
to decrease to half their peak value) to be 18 h in the present
intracerebral LPS model. While this shows an ability of the brain
to clear a substantial influx of neutrophils rapidly, it is interesting
to consider this is likely slower than described for analogous
systemic models (41). Thus, while there are a number of shared
features of acute inflammation triggered inside and outside the
brain, there are also likely location-dependent properties as we
recently demonstrated (30).
An important conceptual principle to emerge that underpins
how inflammation is brought under control outside the brain
is that it involves active induction of pro-resolution cellular
and molecular processes and is not simply the waning of
the initial inflammatory response (63). In the present study,
there are several observations that support a highly active
resolution phase in the acutely inflamed CNS. This includes
the temporal pattern of CNS macrophage accumulation and
reactivity. Using differential CD45 expression by flow cytometry
we were able to identify both resident microglial and infiltrating
monocyte sources of CNSmacrophages in the LPS-injected brain,
which importantly we validated the specificity of using Ccr2-
RFP monocyte reporter mice. Infiltration of monocyte-derived
macrophages peaked 3 d after LPS coinciding with the onset
of resolution. At a similar time (3–5 d after LPS), microglial
numbers peaked although we note this involved only a modest
and statistically non-significant increase. During this time-frame,
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the most visible morphological signs of CNS macrophage
(IBA1+) reactivity were also observed. Furthermore, surface
protein expression levels of CD45 and F4/80 specifically on
microglia steadily increased to reach a peak 3–5 d after LPS again
coinciding with the resolution phase and loss of neutrophils.
Expression of the genes encoding CD45 (Ptprc) and F4/80
(Emr1) followed a similar pattern. CD45 and F4/80 are induced
by microglial/macrophage activation and/or differentiation and
across the time-course studied here provide an indication of
relative temporal changes in magnitude of gross microglial
activation. Together, these data indicate that accumulation and
indices of reactivity of CNS macrophages reach their maximum
during the onset and progression of resolution. Mononuclear
phagocytes have previously been shown to participate in several
aspects of a resolving inflammatory process including through
efferocytosis of neutrophils, provision of trophic and growth
factors and signaling to stromal and other immune cells
(25, 64, 65). Our data are therefore suggestive of resolution-
promoting active changes in CNS macrophage composition and
reactivity. While the aforementioned cellular kinetics point to
the involvement of differentiated myeloid cell populations, the
phenotypic markers we used cannot enable distinction from cells
with immature myeloid status such as MDSCs (47). Originally
described in the tumor microenvironment, but now identified in
various pathological and inflammatory conditions (66), MDSCs
have potent immunoregulatory activities and thus may be
relevant to resolving inflammation. Their identification requires
functional assays and future studies will be needed to determine
their presence at different inflammation phases. Furthermore,
future studies targeting specific mononuclear phagocyte subsets
will be required to confirm their individual and collective
functional roles in resolution.
Perhaps the most striking evidence that the resolution phase
in the present model involves actively induced cell and molecular
programmes comes from the transcriptomic profiling identifying
distinct gene signatures associated with inflammation induction
and resolution. Using an unbiased gene coexpression network
approach, we identified a cluster of coexpressed genes with largely
selective (or substantially greater) induction in expression during
the resolution phase thus confirming active de novo gene network
reprogramming as an integral CNS resolution event. A number of
molecular classes of genes were contained within this cluster and
their coexpressed pattern implicates likely coordinated functions
of their encoded proteins and co-regulation by common
transcription factors. Here, we discuss some particularly notable
features of the resolution gene cluster and their contrasts with the
induction phase cluster (see Supplementary Table 1 for overview
of wider cluster composition and associated biology for all
gene clusters).
One of the most prominent classes of genes in the
resolution cluster was the lysosomal group that included genes
encoding multiple cathepsins, lysozyme, several other lipid-
targeted proteases, and lysosomalmembrane proteins. Lysosomal
function is critical to phagocytic removal of cells and debris,
and our data may reflect this role in the rapid loss of
neutrophils by mononuclear phagocytes in the current model.
Lysosomes also act as a convergence point for autophagy- and
phagocytosis-derived intra- and extra-cellular materials, and
pro-resolving functions of macrophages, including phagocytosis,
were associated with enhanced autophagy (67). A further
important function for lysosomal proteases is the processing of
peptide antigens for presentation on MHC class II (49). Our
data showed a marked switch in the classes of MHC genes
induced from the induction (MHC-I) to resolution (MHC-II)
clusters. This may be similar to the enrichment of resolution-
phase macrophages in the peritoneum for MHC-II-related genes
(68) and suggests antigen presentation and links between innate
and adaptive immune processes may be important for resolution
(65). Although we did not assess lymphocyte subsets in the
current study, increased expression of several T cell and B cell
chemoattractants in LPS-challenged mice was evident in our
transcriptome dataset. Overall, the array of lysosomal proteases
induced during resolutionmay therefore havemultiple functions.
The resolution cluster also contained a large group of genes
encoding proteins involved in lipid scavenging and metabolism,
particularly apolipoproteins and including the major lipid
transport protein of the CNS, apolipoprotein E (69). The
increased expression of these mediators may be important to
provide increased capacity for sequestering, processing and
recycling lipid components of dying or phagocytosed cells and
it is logical to observe coexpression of these genes alongside the
lysosomal genes described above. Cd5l, part of the resolution
cluster, and a gene that lies at the intersection of lipid metabolic
and immune regulation (70) further highlights how altered
lipid metabolism may be an integral component of successful
inflammation resolution.
The resolution cluster contained several transcription
factors associated with reactivity and differentiation of
microglia/macrophages (e.g., Ets1, Irf8, Mafb, Spib) (71–73)
consistent with cellular data discussed above and suggesting
possible key control hubs of resolution gene networks,
including those within the resolution cluster. The identity
of these resolution-phase transcription factors was particularly
noteworthy when contrasted with the induction cluster. Genes
encoding NF-κB, interferon response factors (IRFs) and STAT
proteins were prominent in the induction cluster and in keeping
with the array of MHC-I, interferon and interleukin genes
induced at the induction phase that are known targets of these
transcriptional regulators. Thus, our data highlight not only
marked shifts in multiple functionally-linked gene networks as
the inflammatory response transitions to resolution but also in
the upstream transcriptional control pathways that are likely
governing this transition.
We and other groups have recently described transcriptome-
wide profiles defining the identity and diversity of rodent
microglia in the steady-state (46, 51, 52). Expression of a
unique “homeostatic” gene set is a defining feature of microglia
in the non-pathologic CNS and altered expression of genes
within this homeostatic cluster can indicate deviations toward
reactive phenotypes through sensing of tissue distress signals
(74). Recent studies have identified discrete subsets/states of
microglia that emerge during the progression of pathology in
neurodegenerative diseasemodels that in part involves repression
of some constitutively-expressed homeostatic genes (75). We
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observed marked suppression of the homeostatic genes P2ry12
and P2ry13 during the induction phase that was largely restored
during resolution. This is similar to LPS-induced suppression
of these genes in cultured microglia. The resolution cluster
contained many other homeostatic genes (e.g., Fcrls, Hexb,
Olfml3, Tmem119) and their selective induction during the
resolution phase alongside restored P2ry12/13 expression is
intriguing. The transcriptome data are derived from tissue
homogenates therefore we cannot completely exclude that
this pattern could reflect cell composition (e.g., microglial
cell numbers). However, this is unlikely because there were
negligible differences in microglial numbers quantified by flow
cytometry during the progression of the inflammatory response.
Moreover, the suppression of P2ry12/13 at the same time as
induction of large arrays of cytokine and other inflammatory
gene families suggests phenotypic changes in microglia are a
more likely explanation. Restoration of a homeostatic microglial
phenotype may be an important element of inflammation
resolution however if this is a largely end-stage effect or if
the induction of homeostatic networks is actively involved in
resolution cannot be concluded from the selected timepoints we
studied. With more extensive temporal profiling and single cell
transcriptomics it could be possible to identify if initial deviation
from a homeostatic state is necessary for microglia to engage
a reactive pro-resolution phenotype that subsequently returns
toward a pre-inflamed steady-state profile. This question mirrors
the current debate around the possible harms and benefits of
microglia deviating from their homeostatic state during disease
(54) and will be important to address so that contexts where
controlled manipulation of microglia to promote retention or
deviation from steady-state will be beneficial can be determined.
In the present study, we have focussed on understanding key
cellular and molecular changes in a model of self-limiting brain
inflammation largely focussing on the early stage of resolution
during which clearance of initial inflammatory cell infiltrates
is prominent. Resolution will involve an array of coordinated
processes and may involve more chronic changes that are
important for long-term restoration of tissue homeostasis. We
acknowledge these will be important to study and build upon
the framework presented here. For example, and as implicated
by our transcriptome profiling discussed above, understanding
how the microglial population returns to true steady state
in the later resolution phase will be important. Defining the
phenotypic and functional complexity within the gross myeloid
populations we studied here will also be necessary and likely
require high-dimensional profiling at single cell resolution to
identify if there are particular subclasses/substates of myeloid
cells (mature and MDSCs) particularly important for driving
inflammation resolution. We also acknowledge that this study
has used only male mice at a young adult age therefore systematic
comparison of the effects of sex and age are warranted. In
conclusion, we have shown how resolution of acute inflammation
in the brain involves active induction of cellular and molecular
events, have identified candidate gene networks that may regulate
resolution-phase adaptations and propose the current model as
a useful benchmark and framework for further understanding
mechanisms and modifiers of inflammation resolution in
the brain. The data also imply that inflammation-modifying
strategies to treat CNS pathology are unlikely to be optimal if
they are too indiscriminate and suppressive of adaptive changes
integral to pro-resolution mechanisms.
ETHICS STATEMENT
This study was carried out in accordance with the Animals
(Scientific Procedures) Act 1986 and Directive 2010/63/EU. The
protocol was approved by the local Animal Welfare and Ethics
Review Board (AWERB).
AUTHOR CONTRIBUTIONS
BM conceived study. BM and CD designed and performed
experiments and analyzed all data. AP contributed to analysis and
presentation of transcriptomic data. All authors contributed to
manuscript writing and editing.
FUNDING
This work was funded by a BBSRC Doctoral Training Grant
to CD and grants from BBSRC (BB/J004332/1) and MRC
(MR/L003384/1, MR/R001316/1) to BM.
ACKNOWLEDGMENTS
We thank staff in the Roslin Institute Biological Research Facility
for animal husbandry and technical assistance and Dr. Anna
Raper for assistance with flow cytometry. We are grateful to
Dr. Daniel Anthony (University of Oxford) for kind provision
of the SJC antibody. Microarrays were performed by Edinburgh
Genomics (http://genomics.ed.ac.uk/).
SUPPLEMENTARY MATERIAL




1. Nathan C, Ding A. Nonresolving inflammation. Cell. (2010) 140:871–82.
doi: 10.1016/j.cell.2010.02.029
2. Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin
Invest. (2017) 127:3577–87. doi: 10.1172/JCI90609
3. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of
inflammation in Alzheimer disease. Nat Rev Neurosci. (2015) 16:358–72.
doi: 10.1038/nrn3880
4. Amor S, Puentes F, Baker D, van der Valk P. Inflammation
in neurodegenerative diseases. Immunology. (2010) 129:154–69.
doi: 10.1111/j.1365-2567.2009.03225.x
Frontiers in Immunology | www.frontiersin.org 17 May 2019 | Volume 10 | Article 1048
Davies et al. Inflammation Resolution in the Brain
5. Colonna M, Butovsky O. Microglia function in the central nervous system
during health and neurodegeneration. Ann Rev Immunol. (2017) 35:441–68.
doi: 10.1146/annurev-immunol-051116-052358
6. Colonna M, Wang Y. TREM2 variants: new keys to decipher
Alzheimer disease pathogenesis. Nat Rev Neurosci. (2016) 17:201–7.
doi: 10.1038/nrn.2016.7
7. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to
translation. Nat Med. (2011) 17:796–808. doi: 10.1038/nm.2399
8. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection
in traumatic brain injury. JAMA Neurol. (2015) 72:355–62.
doi: 10.1001/jamaneurol.2014.3558
9. Kokiko-Cochran ON, Godbout JP. The inflammatory continuum of traumatic
brain injury and Alzheimer’s disease. Front Immunol. (2018) 9:672.
doi: 10.3389/fimmu.2018.00672
10. Faden AI, Wu J, Stoica BA, Loane DJ. Progressive inflammation-mediated
neurodegeneration after traumatic brain or spinal cord injury. Br J Pharmacol.
(2016) 173:681–91. doi: 10.1111/bph.13179
11. Chen A, Oakley AE,MonteiroM, Tuomela K, Allan LM,Mukaetova-Ladinska
EB, et al. Multiplex analyte assays to characterize different dementias: brain
inflammatory cytokines in poststroke and other dementias. Neurobiol Aging.
(2016) 38:56–67. doi: 10.1016/j.neurobiolaging.2015.10.021
12. Denes A, Vidyasagar R, Feng J, Narvainen J, McColl BW, Kauppinen RA, et al.
Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb
Blood Flow Metab. (2007) 27:1941–53. doi: 10.1038/sj.jcbfm.9600495
13. Strecker JK, Schmidt A, Schäbitz WR, Minnerup J. Neutrophil granulocytes
in cerebral ischemia – evolution from killers to key players. Neurochem Int.
(2017) 107:117–26. doi: 10.1016/j.neuint.2016.11.006
14. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus
potentiates the acute phase and CXC chemokine responses to
experimental stroke and exacerbates brain damage via interleukin-1-
and neutrophil-dependent mechanisms. J Neurosci. (2007) 27:4403–12.
doi: 10.1523/JNEUROSCI.5376-06.2007
15. Ransohoff RM. How neuroinflammation contributes to neurodegeneration.
Science. (2016) 353:777–83. doi: 10.1126/science.aag2590
16. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, et al.
Differential roles of microglia and monocytes in the inflamed central nervous
system. J Exp Med. (2014) 211:1533–49. doi: 10.1084/jem.20132477
17. Bottcher C, Priller J. Myeloid cell-based therapies in neurological disorders:
how far have we come? Biochim Biophys Acta. (2016) 1862:323–8.
doi: 10.1016/j.bbadis.2015.10.003
18. Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB.
Transcranial amelioration of inflammation and cell death after brain injury.
Nature. (2014) 505:223–8. doi: 10.1038/nature12808
19. Lampron A, Larochelle A, Laflamme N, Préfontaine P, Plante MM,
Sánchez MG, et al. Inefficient clearance of myelin debris by microglia
impairs remyelinating processes. J Exp Med. (2015) 212:481–95.
doi: 10.1084/jem.20141656
20. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons
without inflammation by microglial triggering receptor expressed on myeloid
cells-2. J. Exp. Med. (2005) 201:647–57. doi: 10.1084/jem.20041611
21. Lou N, Takano T, Pei Y, Xavier AL, Goldman SA, Nedergaard M.
Purinergic receptor P2RY12-dependent microglial closure of the injured
blood-brain barrier. Proc Natl Acad Sci USA. (2016) 113:1074–9.
doi: 10.1073/pnas.1520398113
22. Gliem M, Mausberg AK, Lee JI, Simiantonakis I, van Rooijen N, Hartung
HP, et al. Macrophages prevent hemorrhagic infarct transformation in
murine stroke models. Ann Neurol. (2012) 71:743–52. doi: 10.1002/ana.
23529
23. Stirling DP, Liu S, Kubes P, Yong VW. Depletion of Ly6G/Gr-1 leukocytes
after spinal cord injury in mice alters wound healing and worsens
neurological outcome. J Neurosci Off J Soc Neurosci. (2009) 29:753–64.
doi: 10.1523/JNEUROSCI.4918-08.2009
24. Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J,
et al. Recruitment of beneficial M2 macrophages to injured spinal cord is
orchestrated by remote brain choroid plexus. Immunity. (2013) 38:555–69.
doi: 10.1016/j.immuni.2013.02.012
25. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and
fibrosis. Immunity. (2016) 44:450–62. doi: 10.1016/j.immuni.2016.02.015
26. Wattananit S, Tornero D, Graubardt N, Memanishvili T, Monni E, Tatarishvili
J, et al. Monocyte-derived macrophages contribute to spontaneous long-
term functional recovery after stroke in mice. J Neurosci. (2016) 36:4182–95.
doi: 10.1523/JNEUROSCI.4317-15.2016
27. Chang CF, Goods BA, Askenase MH, Hammond MD, Renfroe SC,
Steinschneider AF, et al. Erythrocyte efferocytosis modulates macrophages
towards recovery after intracerebral hemorrhage. J Clin Invest. (2018)
128:607–24. doi: 10.1172/JCI95612
28. JinWN, Shi SX, Li Z, Li M,Wood K, Gonzales RJ, et al. Depletion of microglia
exacerbates postischemic inflammation and brain injury. J Cereb Blood Flow
Metab. (2017) 37:2224–36. doi: 10.1177/0271678X17694185
29. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke:
role of inflammatory cells. J Leukocyte Biol. (2010) 87:779–89.
doi: 10.1189/jlb.1109766
30. Giles JA, Greenhalgh AD, Davies CL, Denes A, Shaw T, Coutts G, et al.
Requirement for interleukin-1 to drive brain inflammation reveals tissue-
specific mechanisms of innate immunity. Eur J Immunol. (2015) 45:525–30.
doi: 10.1002/eji.201444748
31. Banwell V, Sena ES, Macleod MR. Systematic review and stratified meta-
analysis of the efficacy of interleukin-1 receptor antagonist in animal models
of stroke. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. (2009) 18:269–76.
doi: 10.1016/j.jstrokecerebrovasdis.2008.11.009
32. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ,
et al. A randomised phase II study of interleukin-1 receptor antagonist
in acute stroke patients. J Neurol Neurosurg Psychiatry. (2005) 76:1366–72.
doi: 10.1136/jnnp.2004.054882
33. Sobowale OA, Parry-Jones AR, Smith CJ, Tyrrell PJ, Rothwell NJ, Allan SM.
Interleukin-1 in stroke: from bench to bedside. Stroke J Cereb Circ. (2016)
47:2160–7. doi: 10.1161/STROKEAHA.115.010001
34. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark
WM, et al. Minocycline to improve neurologic outcome in stroke
(MINOS): a dose-finding study. Stroke J Cereb Circ. (2010) 41:2283–7.
doi: 10.1161/STROKEAHA.110.582601
35. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al.
Minocycline treatment in acute stroke: an open-label, evaluator-blinded study.
Neurology. (2007) 69:1404–10. doi: 10.1212/01.wnl.0000277487.04281.db
36. Vedantam SM, Moller AR. Minocycline: a novel stroke therapy. J Neurol
Stroke. (2015) 2:00073. doi: 10.15406/jnsk.2015.02.00073
37. Veltkamp R, Gill D. Clinical trials of immunomodulation in ischemic
stroke. Neurother J Am Soc Exp NeuroTher. (2016) 13:791–800.
doi: 10.1007/s13311-016-0458-y
38. Drieu A, Levard D, Vivien D, Rubio M. Anti-inflammatory treatments
for stroke: from bench to bedside. Ther Adv Neurol Dis. (2018)
11:1756286418789854. doi: 10.1177/1756286418789854
39. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al.
Final results of MRC CRASH, a randomised placebo-controlled trial of
intravenous corticosteroid in adults with head injury-outcomes at 6 months.
Lancet. (2005) 365:1957–9. doi: 10.1016/S0140-6736(05)66552-X
40. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel
M, et al. Very early administration of progesterone for acute traumatic
brain injury. N Engl J Med. (2014) 371:2457–66. doi: 10.1056/NEJMoa1
404304
41. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH,
et al. Molecular circuits of resolution: formation and actions of resolvins and
protectins. J Immunol. (2005) 174:4345–55. doi: 10.4049/jimmunol.174.7.4345
42. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1
activate inflammation-resolution programmes. Nature. (2007) 447:869–74.
doi: 10.1038/nature05877
43. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the
resolution of inflammation. Curr Opin Pharmacol. (2006) 6:414–20.
doi: 10.1016/j.coph.2006.02.006
44. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation:
novel pro-resolving lipid mediators in resolution. Semin Immunol. (2015)
27:200–15. doi: 10.1016/j.smim.2015.03.004
45. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, et al.
Selective chemokine receptor usage by central nervous system myeloid cells
in CCR2-red fluorescent protein knock-in mice. PLoS ONE. (2010) 5:e13693.
doi: 10.1371/journal.pone.0013693
Frontiers in Immunology | www.frontiersin.org 18 May 2019 | Volume 10 | Article 1048
Davies et al. Inflammation Resolution in the Brain
46. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, et al.
Microglial brain region-dependent diversity and selective regional sensitivities
to aging. Nat Neurosci. (2016) 19:504–16. doi: 10.1038/nn.4222
47. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten
TF, et al. Recommendations for myeloid-derived suppressor cell
nomenclature and characterization standards. Nat Commun. (2016) 7:12150.
doi: 10.1038/ncomms12150
48. Goldmann T, Wieghofer P, Jordão MJ, Prutek F, Hagemeyer N, Frenzel K,
et al. Origin, fate and dynamics of macrophages at central nervous system
interfaces. Nat Immunol. (2016) 17:797–805. doi: 10.1038/ni.3423
49. Watts C. The endosome-lysosome pathway and information generation
in the immune system. Biochim Biophys Acta. (2012) 1824:14–21.
doi: 10.1016/j.bbapap.2011.07.006
50. Chiu IM, Heesters BA, Ghasemlou N, Von Hehn CA, Zhao F, Tran J, et al.
Bacteria activate sensory neurons that modulate pain and inflammation.
Nature. (2013) 501:52–7. doi: 10.1038/nature12479
51. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means
TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat
Neurosci. (2013) 16:1896–905. doi: 10.1038/nn.3554
52. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely
G, et al. Identification of a unique TGF-[beta]-dependent molecular
and functional signature in microglia. Nat Neurosci. (2014) 17:131–43.
doi: 10.1038/nn.3599
53. Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E,
et al. An environment-dependent transcriptional network specifies human
microglia identity. Science. (2017) 356:eaal3222. doi: 10.1126/science.aal3222
54. Butovsky O, Weiner HL. Microglial signatures and their role in health and
disease. Nat Rev Neurosci. (2018) 19:622–35. doi: 10.1038/s41583-018-0057-5
55. Colonna M. TREMs in the immune system and beyond. Nat Rev. (2003)
3:445–53. doi: 10.1038/nri1106
56. Forrester JV, McMenamin PG, Dando SJ. CNS infection
and immune privilege. Nat Rev Neurosci. (2018) 19:655–71.
doi: 10.1038/s41583-018-0070-8
57. Koedel U, Frankenberg T, Kirschnek S, Obermaier B, Häcker H, Paul R, et al.
Apoptosis is essential for neutrophil functional shutdown and determines
tissue damage in experimental pneumococcal meningitis. PLoS Pathog. (2009)
5:e1000461. doi: 10.1371/journal.ppat.1000461
58. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat
Rev. (2008) 8:279–89. doi: 10.1038/nri2215
59. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or
assistants? J Leukocyte Biol. (2010) 87:989–99. doi: 10.1189/jlb.12
09775
60. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid
mediators: a new pharmacologic genus. Br J Pharmacol. (2008) 153:S200–15.
doi: 10.1038/sj.bjp.0707489
61. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class
switching during acute inflammation: signals in resolution. Nat Immunol.
(2001) 2:612–9. doi: 10.1038/89759
62. Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, Bystrom
J. A new strategy for the identification of novel molecules with targeted
proresolution of inflammation properties. J Immunol. (2010) 184:1516–25.
doi: 10.4049/jimmunol.0902866
63. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, et al.
Resolution of inflammation: state of the art, definitions and terms. FASEB J.
(2007) 21:325–32. doi: 10.1096/fj.06-7227rev
64. Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of
inflammation: an integrated view. EMBO Mol Med. (2013) 5:661–74.
doi: 10.1002/emmm.201202382
65. Newson J, Stables M, Karra E, Arce-Vargas F, Quezada S, Motwani M, et al.
Resolution of acute inflammation bridges the gap between innate and adaptive
immunity. Blood. (2014) 124:1748–64. doi: 10.1182/blood-2014-03-562710
66. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming
of age. Nat Immunol. (2018) 19:108–19. doi: 10.1038/s41590-017-0022-x
67. Prieto P, Rosales-Mendoza CE, Terrón V, Toledano V, Cuadrado
A, López-Collazo E, et al. Activation of autophagy in macrophages
by pro-resolving lipid mediators. Autophagy. (2015) 11:1729–44.
doi: 10.1080/15548627.2015.1078958
68. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, et al.
Transcriptomic analyses of murine resolution-phase macrophages. Blood.
(2011) 118:e192–208. doi: 10.1182/blood-2011-04-345330
69. Mahley RW. Central nervous system lipoproteins: ApoE and regulation of
cholesterol metabolism. Arterioscler Thromb Vasc Biol. (2016) 36:1305–15.
doi: 10.1161/ATVBAHA.116.307023
70. Sanjurjo L, Aran G, Roher N, Valledor AF, Sarrias MR. AIM/CD5L: a key
protein in the control of immune homeostasis and inflammatory disease. J
Leukocyte Biol. (2015) 98:173–84. doi: 10.1189/jlb.3RU0215-074R
71. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, et al.
IRF8 is a critical transcription factor for transformingmicroglia into a reactive
phenotype. Cell Rep. (2012) 1:334–40. doi: 10.1016/j.celrep.2012.02.014
72. Cuevas VD, Anta L, Samaniego R, Orta-Zavalza E, Vladimir de la
Rosa J, Baujat G, et al. MAFB determines human macrophage anti-
inflammatory polarization: relevance for the pathogenic mechanisms
operating in multicentric carpotarsal osteolysis. J Immunol. (2017) 198:2070–
81. doi: 10.4049/jimmunol.1601667
73. Yu T, Guo W, Tian Y, Xu J, Chen J, Li L, et al. Distinct regulatory networks
control the development of macrophages of different origins in zebrafish.
Blood. (2017) 129:509–19. doi: 10.1182/blood-2016-07-727651
74. Song WM, Colonna M. The identity and function of microglia
in neurodegeneration. Nat Immunol. (2018) 19:1048–58.
doi: 10.1038/s41590-018-0212-1
75. Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M,
Amit I. Disease-associated microglia: a universal immune sensor of
neurodegeneration. Cell. (2018) 173:1073–81. doi: 10.1016/j.cell.2018.05.003
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Davies, Patir andMcColl. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 19 May 2019 | Volume 10 | Article 1048
